331A — Medix Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Medix, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 4,273 | 4,180 | 4,162 | 4,257 |
| Cost of Revenue | ||||
| Gross Profit | 3,692 | 3,738 | 3,728 | 3,702 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 3,667 | 3,395 | 3,359 | 3,597 |
| Operating Profit | 606 | 785 | 803 | 659 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 637 | 788 | 952 | 662 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 402 | 489 | 804 | 435 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | 402 | 489 | 804 | 437 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Dilution Adjustment | ||||
| Diluted Net Income | 402 | 489 | 804 | 437 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 63.6 | 61.8 | 99.5 | 56.7 |
| Dividends per Share |